These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 31548533)

  • 1. Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma.
    Cho SF; Lin L; Xing L; Yu T; Wen K; Anderson KC; Tai YT
    Antibodies (Basel); 2017 Nov; 6(4):. PubMed ID: 31548533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
    Campbell KS; Cohen AD; Pazina T
    Front Immunol; 2018; 9():2551. PubMed ID: 30455698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
    Sherbenou DW; Mark TM; Forsberg P
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances and practical use of monoclonal antibodies in multiple myeloma therapy.
    Lee HC; Weber DM
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):512-520. PubMed ID: 27913523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic antibodies for multiple myeloma.
    Ishida T
    Jpn J Clin Oncol; 2018 Nov; 48(11):957-963. PubMed ID: 30329116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab.
    Chen WC; Kanate AS; Craig M; Petros WP; Hazlehurst LA
    Cancer Manag Res; 2017; 9():307-314. PubMed ID: 28744161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date.
    Weisel K
    Onco Targets Ther; 2016; 9():6037-6048. PubMed ID: 27785050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab.
    Einsele H; Schreder M
    Ther Adv Hematol; 2016 Oct; 7(5):288-301. PubMed ID: 27695618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combination therapy with monoclonal antibodies for treatment of newly diagnosed multiple myeloma].
    Nishimura N; Terui Y; Hatake K
    Rinsho Ketsueki; 2017; 58(8):1006-1013. PubMed ID: 28883263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
    Afifi S; Michael A; Lesokhin A
    Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma.
    Franssen LE; Stege CAM; Zweegman S; van de Donk NWCJ; Nijhof IS
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32331242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reprint of "Immunomodulatory effects of CD38-targeting antibodies".
    van de Donk NWCJ
    Immunol Lett; 2019 Jan; 205():71-77. PubMed ID: 30826127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daratumumab: monoclonal antibody therapy to treat multiple myeloma.
    Xia C; Ribeiro M; Scott S; Lonial S
    Drugs Today (Barc); 2016 Oct; 52(10):551-560. PubMed ID: 27910963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma.
    D'Agostino M; Gazzera G; Cetani G; Bringhen S; Boccadoro M; Gay F
    Curr Med Chem; 2019; 26(32):5968-5981. PubMed ID: 29756564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma.
    Radocha J; van de Donk NWCJ; Weisel K
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33805481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulatory effects of CD38-targeting antibodies.
    van de Donk NWCJ
    Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal Antibodies in the Treatment of Multiple Myeloma.
    van de Donk NWCJ; Zweegman S
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):337-360. PubMed ID: 38151402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
    Palumbo A; Sonneveld P
    Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.